亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure

阿巴塔克普 医学 美罗华 临床终点 风湿病 内科学 托珠单抗 物理疗法 临床试验 类风湿性关节炎 淋巴瘤
作者
Suzanne Arends,Liseth de Wolff,Jolien F. van Nimwegen,Gwenny M. P. J. Verstappen,Jelle Vehof,Michele Bombardieri,Simon Bowman,Elena Pontarini,Alan N. Baer,Marleen Nys,Jacques‐Eric Gottenberg,Renaud Felten,Neelanjana Ray,Arjan Vissink,Frans G. M. Kroese,Hendrika Bootsma
出处
期刊:The Lancet Rheumatology [Elsevier BV]
卷期号:3 (8): e553-e562 被引量:99
标识
DOI:10.1016/s2665-9913(21)00122-3
摘要

Summary

Background

Recent randomised controlled trials (RCTs) in primary Sjögren's syndrome used the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) as their primary endpoint. Given the heterogeneous and complex nature of primary Sjögren's syndrome, it might be more appropriate to also assess other clinically relevant disease features. We aimed to develop a novel composite endpoint for assessing treatment efficacy in patients with primary Sjögren's syndrome: the Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS).

Methods

A multidisciplinary expert team selected clinically relevant items and candidate measurements for inclusion in the composite score. For each measurement, cutoff points for response to treatment were chosen based on expert opinion, previously published data on minimal clinically important improvements, and trial data, primarily the week-24 data of the single-centre ASAP-III trial of abatacept versus placebo. CRESS was validated using data from three independent RCTs: one trial of rituximab (TRACTISS), one of abatacept (multinational trial), and one of tocilizumab (ETAP). We calculated the number and percentage of patients who were responders in the separate CRESS items, and the percentage of responders based on the total CRESS at the primary endpoint visits (week 48 for TRACTISS, week 24 for the other two trials). Patients with fewer than three items available for evaluating CRESS response were imputed as non-responders.

Findings

Based on expert opinion, five complementary items were selected to assess response: (1) systemic disease activity by Clinical ESSDAI (less than 5 points); (2) patient-reported symptoms by EULAR Sjögren's Syndrome Patient Reported Index, assessed by a decrease of at least 1 point or at least 15% from baseline; (3) tear gland item by Schirmer's test and ocular staining score, assessed by an increase of at least 5 mm or decrease of at least 2 points, respectively, in patients with abnormal Schirmer's test or ocular staining score findings at baseline, or, in patients with normal baseline values, assessed by no change to abnormal for both; (4) salivary gland item, assessed by unstimulated whole saliva secretion (increase of at least 25%) and salivary gland ultrasonography (decrease of at least 25%); and (5) serology, assessed by rheumatoid factor (decrease of at least 25%) and IgG (decrease of at least 10%). Total CRESS response is defined as response on at least three of five items. Post-hoc assessment of phase 3 trial data showed that CRESS response rates at the primary endpoint visits were 60% (24 of 40) for abatacept versus 18% (seven of 39) for placebo (p<0·0001) in ASAP-III, 49% (33 of 67) for rituximab versus 30% (20 of 66) for placebo (p=0·026) in the TRACTISS trial, 45% (41 of 92) for abatacept versus 32% (30 of 95) for placebo (p=0·067) in the multinational abatacept trial, and 18% (10 of 55) for tocilizumab versus 24% (13 of 55) for placebo (p=0·48) in the ETAP trial.

Interpretation

The CRESS is a feasible, well-balanced, composite endpoint for use in trials of primary Sjögren's syndrome. As a next step, the CRESS will require validation in a prospective RCT.

Funding

None.

Translation

For the Dutch translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
威武青寒完成签到,获得积分10
14秒前
11完成签到 ,获得积分10
21秒前
31秒前
31秒前
37秒前
内向的紫槐完成签到,获得积分10
40秒前
42秒前
沉静问芙完成签到,获得积分10
46秒前
小黑桃完成签到,获得积分10
50秒前
jf完成签到 ,获得积分10
55秒前
1分钟前
cc发布了新的文献求助10
1分钟前
科研通AI6.4的应助被祈愿采纳,获得10
1分钟前
qiao完成签到,获得积分10
1分钟前
Maestro_S的应助被cc采纳,获得10
1分钟前
1分钟前
jen完成签到 ,获得积分10
1分钟前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1分钟前
斯文败类的应助被DRJ采纳,获得10
1分钟前
华仔的应助被科研通管家采纳,获得10
1分钟前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1分钟前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1分钟前
科目三的应助被科研通管家采纳,获得30
1分钟前
Ava的应助被科研通管家采纳,获得10
1分钟前
Isaac完成签到,获得积分10
1分钟前
SGD完成签到,获得积分10
1分钟前
corleeang完成签到 ,获得积分10
1分钟前
丰富夏菡完成签到,获得积分10
1分钟前
SGD发布了新的文献求助10
1分钟前
null的应助被Ella采纳,获得10
1分钟前
null的应助被Ella采纳,获得10
1分钟前
1分钟前
azhiyuan完成签到,获得积分10
1分钟前
搜集达人的应助被DRJ采纳,获得10
1分钟前
科研通AI6.4的应助被SUNny采纳,获得10
1分钟前
九灶完成签到 ,获得积分10
1分钟前
null的应助被Ella采纳,获得10
1分钟前
1分钟前
null的应助被Ella采纳,获得10
1分钟前
小黑桃发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165939
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749898
捐赠科研通 7756692
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553385
邀请新用户注册赠送积分活动 2473623